Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:SUPN
- CUSIP: 86845910
- Web: www.supernus.com
Capitalization:- Market Cap: $2.12466 billion
- Outstanding Shares: 50,282,000
Average Prices:- 50 Day Moving Avg: $41.78
- 200 Day Moving Avg: $32.37
- 52 Week Range: $17.25 - $44.95
P/E:- Trailing P/E Ratio: 22.70
- Foreward P/E Ratio: 25.73
- P/E Growth: 1.55
Sales & Book Value:- Annual Revenue: $228.39 million
- Price / Sales: 9.29
- Book Value: $4.10 per share
- Price / Book: 10.29
Profitability:- EBIDTA: $67.28 million
- Net Margins: 42.46%
- Return on Equity: 31.79%
- Return on Assets: 19.08%
Debt:- Debt-to-Equity Ratio: 0.02%
- Current Ratio: 1.83%
- Quick Ratio: 1.59%
Misc:- Average Volume: 637,862 shs.
- Beta: 1.34
- Short Ratio: 5.1
Frequently Asked Questions for Supernus Pharmaceuticals (NASDAQ:SUPN)
What is Supernus Pharmaceuticals' stock symbol?
Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
How were Supernus Pharmaceuticals' earnings last quarter?
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its earnings results on Tuesday, May, 9th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by $0.03. The business had revenue of $57.58 million for the quarter, compared to analysts' expectations of $57.91 million. Supernus Pharmaceuticals had a return on equity of 31.79% and a net margin of 42.46%. View Supernus Pharmaceuticals' Earnings History.
When will Supernus Pharmaceuticals make its next earnings announcement?
Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2017?
6 brokers have issued 12 month price objectives for Supernus Pharmaceuticals' stock. Their forecasts range from $34.00 to $51.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $45.67 in the next year. View Analyst Ratings for Supernus Pharmaceuticals.
What are analysts saying about Supernus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (7/18/2017)
- 2. Jefferies Group LLC analysts commented, "Following Monday's Zydus settlement, SUPN reached a similar agreement with TEVA on the Trokendi XR (TXR) patent challenge ' allowing generic entry starting January 2023. There is now much more certainty in SUPN's ability to maintain cash flows from 76% of its current epilepsy franchises at least through 2022 and another 24% through 2027 (OXR), bridging to the latestage pipeline, which should come online in 2020. Importantly, SUPN fits with our M&A thesis." (3/8/2017)
- 3. Cantor Fitzgerald analysts commented, "SUPN announced the settlement of a Paragraph 4 challenge to Trokendi XR patents by Zydus allowing generic entry on or before 1/1/2023." (3/7/2017)
Who are some of Supernus Pharmaceuticals' key competitors?
Some companies that are related to Supernus Pharmaceuticals include Indivior PLC (INDV), Advanced Accelerator Applications S.A. (AAAP), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Aimmune Therapeutics (AIMT), Rockwell Medical (RMTI), Assembly Biosciences (ASMB), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are Supernus Pharmaceuticals' key executives?
Supernus Pharmaceuticals' management team includes the folowing people:
- Charles W. Newhall III, Independent Chairman of the Board
- Jack A. Khattar, President, Chief Executive Officer, Secretary, Director
- Gregory S. Patrick, Chief Financial Officer, Vice President
- Stefan K. F. Schwabe M.D. Ph.D., Executive Vice-President - Research and Development, Chief Medical Officer
- Padmanabh P. Bhatt Ph.D., Senior Vice President - Intellectual Property, Chief Scientific Officer
- Victor Vaughn, Senior Vice President - Sales and Marketing
- Georges Gemayel Ph.D., Independent Director
- Frederick M. Hudson CPA, Independent Director
- William A. Nuerge, Independent Director
- John M. Siebert Ph.D., Independent Director
Who owns Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Capital Management Corp VA (0.23%), Bank of Montreal Can (0.09%), US Bancorp DE (0.08%), Juncture Wealth Strategies LLC (0.07%), Franklin Street Advisors Inc. NC (0.06%) and Capital Impact Advisors LLC (0.06%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, M James Barrett and Padmanabh P Bhatt. View Institutional Ownership Trends for Supernus Pharmaceuticals.
Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Juncture Wealth Strategies LLC, Capital Impact Advisors LLC, Capital Management Corp VA, US Bancorp DE, Franklin Street Advisors Inc. NC, Capstone Asset Management Co. and Thomson Horstmann & Bryant Inc.. Company insiders that have sold Supernus Pharmaceuticals stock in the last year include Gregory S Patrick and Padmanabh P Bhatt. View Insider Buying and Selling for Supernus Pharmaceuticals.
Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Legato Capital Management LLC, Adams Diversified Equity Fund Inc., NEXT Financial Group Inc, Sheets Smith Wealth Management, Eqis Capital Management Inc., Creative Planning, Aperio Group LLC and State of Alaska Department of Revenue. View Insider Buying and Selling for Supernus Pharmaceuticals.
How do I buy Supernus Pharmaceuticals stock?
Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Supernus Pharmaceuticals' stock price today?
One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $42.20.
MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $45.67 (8.21% upside) |
Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/18/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $36.00 -> $47.00 | Medium |  |
| 7/17/2017 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | $46.00 | High | |
| 7/14/2017 | Janney Montgomery Scott | Initiated Coverage | Neutral -> Neutral | $47.00 | Low | |
| 7/5/2017 | Cantor Fitzgerald | Boost Price Target | Buy | $34.00 -> $49.00 | Medium | |
| 6/28/2017 | Jefferies Group LLC | Boost Price Target | Buy | $45.00 -> $51.00 | High | |
| 5/11/2017 | Cowen and Company | Boost Price Target | Outperform | $31.00 -> $34.00 | Low | |
| 7/18/2016 | Northland Securities | Downgrade | Outperform -> Market Perform | $24.00 | N/A | |
(Data available from 7/22/2015 forward)
Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)Earnings History by Quarter for Supernus Pharmaceuticals (NASDAQ SUPN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/31/2017 | | | | | | | | |
| 5/9/2017 | Q1 2017 | $0.22 | $0.19 | $57.91 million | $57.58 million | View | Listen | |
| 8/2/2016 | Q2 | $0.13 | $0.18 | $49.67 million | $50.40 million | View | Listen | |
| 5/3/2016 | Q1 | $0.09 | $0.08 | $45.33 million | $43.00 million | View | Listen | |
| 3/2/2016 | Q4 | $0.06 | $0.14 | $42.93 million | $42.70 million | View | Listen | |
| 11/3/2015 | Q315 | $0.02 | $0.08 | $37.93 million | $38.60 million | View | Listen | |
| 8/5/2015 | Q215 | $0.02 | $0.03 | $34.07 million | $35.10 million | View | Listen | |
| 5/5/2015 | | $0.02 | $0.02 | $29.16 million | $28.13 million | View | Listen | |
| 11/11/2014 | Q314 | $0.36 | $0.39 | $43.10 million | $52.50 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.16) | $0.08 | $19.85 million | $29.67 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.41) | ($0.38) | $9.94 million | $9.00 million | View | N/A | |
| 3/12/2014 | Q413 | ($0.55) | ($0.65) | $7.78 million | $10.30 million | View | N/A | |
| 11/12/2013 | Q313 | ($0.67) | ($0.78) | $2.54 million | $1.26 million | View | Listen | |
| 8/13/2013 | Q2 2013 | ($0.65) | ($0.89) | $0.91 million | $0.28 million | View | N/A | |
| 11/7/2012 | Q312 | ($0.62) | ($0.55) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)2017 EPS Consensus Estimate: $1.04
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.16 | $0.24 | $0.20 |
| Q2 2017 | 2 | $0.23 | $0.24 | $0.24 |
| Q3 2017 | 1 | $0.24 | $0.24 | $0.24 |
| Q4 2017 | 2 | $0.23 | $0.49 | $0.36 |
(Data provided by Zacks Investment Research)
Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Supernus Pharmaceuticals (NASDAQ:SUPN)Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 90.95%
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/12/2017 | Padmanabh P Bhatt | VP | Sell | 3,735 | $44.90 | $167,701.50 | |
| 6/23/2017 | Padmanabh P Bhatt | VP | Sell | 2,556 | $44.90 | $114,764.40 | |
| 6/2/2017 | Padmanabh P Bhatt | VP | Sell | 10,000 | $39.86 | $398,600.00 | |
| 5/26/2017 | Padmanabh P Bhatt | VP | Sell | 2,500 | $35.90 | $89,750.00 | |
| 5/25/2017 | Padmanabh P Bhatt | VP | Sell | 5,500 | $34.90 | $191,950.00 | |
| 4/24/2017 | Gregory S Patrick | CFO | Sell | 54,000 | $32.37 | $1,747,980.00 | |
| 4/24/2017 | Padmanabh P Bhatt | VP | Sell | 11,806 | $32.59 | $384,757.54 | |
| 9/16/2016 | Gregory S Patrick | CFO | Sell | 2,000 | $25.00 | $50,000.00 | |
| 7/14/2016 | Gregory S. Patrick | CFO | Sell | 3,395 | $22.00 | $74,690.00 | |
| 4/11/2016 | Padmanabh P Bhatt | VP | Sell | 30,762 | $16.49 | $507,265.38 | |
| 12/9/2015 | Padmanabh P. Bhatt | VP | Sell | 14,238 | $14.90 | $212,146.20 | |
| 12/8/2015 | M James Barrett | Director | Sell | 212,970 | $14.56 | $3,100,843.20 | |
| 11/25/2015 | M James Barrett | Director | Sell | 16,179 | $16.35 | $264,526.65 | |
| 11/18/2015 | M James Barrett | Director | Sell | 93,000 | $16.61 | $1,544,730.00 | |
| 11/16/2015 | M James Barrett | Director | Sell | 119,650 | $16.24 | $1,943,116.00 | |
| 11/4/2015 | Padmanabh P Bhatt | VP | Sell | 5,000 | $19.90 | $99,500.00 | |
| 7/16/2015 | Gregory S Patrick | CFO | Sell | 6,217 | $20.00 | $124,340.00 | |
| 7/13/2015 | Stefan K.F. Schwabe | EVP | Sell | 1,950 | $19.23 | $37,498.50 | |
| 6/17/2015 | M James Barrett | Director | Sell | 111,881 | $16.39 | $1,833,729.59 | |
| 6/17/2015 | Scott D Sandell | Major Shareholder | Sell | 136,597 | $16.50 | $2,253,850.50 | |
| 6/16/2015 | M James Barrett | Director | Sell | 55,105 | $16.85 | $928,519.25 | |
| 6/16/2015 | Scott D Sandell | Major Shareholder | Sell | 95,437 | $16.92 | $1,614,794.04 | |
| 6/12/2015 | Stefan K.F. Schwabe | EVP | Sell | 2,051 | $18.27 | $37,471.77 | |
| 6/11/2015 | Stefan K.F. Schwabe | EVP | Sell | 3,631 | $16.39 | $59,512.09 | |
| 3/24/2015 | Jones W Bryan | VP | Sell | 1,900 | $12.00 | $22,800.00 | |
| 8/19/2013 | Padmanabh Bhatt | VP | Sell | 2,285 | $8.21 | $18,759.85 | |
| 3/22/2013 | Michael Bigham | Director | Buy | 35,000 | $5.41 | $189,350.00 | |
| 3/21/2013 | John M Siebert | Director | Buy | 3,000 | $5.50 | $16,500.00 | |
| 3/15/2013 | Jack A Khattar | CEO | Buy | 10,000 | $6.15 | $61,500.00 | |
| 3/14/2013 | Gregory S Patrick | CFO | Buy | 5,000 | $6.95 | $34,750.00 | |
| 12/4/2012 | John M Siebert | Director | Buy | 7,000 | $8.14 | $56,980.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Supernus Pharmaceuticals (NASDAQ:SUPN)
Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
| Source: |
|
| Date | Headline |
|---|
 | Supernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $68.54 Million
www.americanbankingnews.com - July 20 at 3:22 PM |
 | Supernus to Host Second Quarter 2017 Earnings Conference Call - GlobeNewswire (press release)
globenewswire.com - July 20 at 8:13 AM |
 | Supernus to Host Second Quarter 2017 Earnings Conference Call
finance.yahoo.com - July 20 at 8:13 AM |
 | Lightning Round: Jim Cramer Advises Viewers On Chegg, Opko Health And More - Benzinga
www.benzinga.com - July 19 at 7:51 AM |
| Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 3,735 Shares
www.americanbankingnews.com - July 14 at 8:26 PM |
| Supernus Pharmaceuticals, Inc. (SUPN) Now Covered by Janney Montgomery Scott
www.americanbankingnews.com - July 14 at 9:10 AM |
| Aimmune Therapeutics (AIMT) & Supernus Pharmaceuticals (SUPN) Head-To-Head Contrast
www.americanbankingnews.com - July 13 at 12:26 PM |
| ETFs with exposure to Supernus Pharmaceuticals, Inc. : July 12, 2017
finance.yahoo.com - July 13 at 10:03 AM |
| Supernus Pharmaceuticals Inc (NASDAQ:SUPN) PT Raised to $49.00
www.americanbankingnews.com - July 9 at 8:28 PM |
| Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Expected to Post FY2017 Earnings of $1.10 Per Share
www.americanbankingnews.com - July 7 at 10:52 AM |
| Supernus Pharmaceuticals, Inc. to Post FY2018 Earnings of $1.93 Per Share, Cantor Fitzgerald Forecasts (SUPN)
www.americanbankingnews.com - July 6 at 11:50 AM |
 | Strange: Bullish SUPN Analysts Actually See -3.33% Downside - Nasdaq
www.nasdaq.com - July 4 at 7:43 AM |
| Supernus Pharmaceuticals, Inc. (SUPN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 3 at 4:58 PM |
| Reviewing Supernus Pharmaceuticals (SUPN) and TherapeuticsMD (TXMD)
www.americanbankingnews.com - July 1 at 10:04 PM |
| ETFs with exposure to Supernus Pharmaceuticals, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 7:56 AM |
| Jefferies Group Research Analysts Cut Earnings Estimates for Supernus Pharmaceuticals, Inc. (SUPN)
www.americanbankingnews.com - June 30 at 8:43 AM |
| Supernus Pharmaceuticals, Inc. (SUPN) Price Target Raised to $51.00 at Jefferies Group LLC
www.americanbankingnews.com - June 28 at 8:19 AM |
| Padmanabh P. Bhatt Sells 2,556 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock
www.americanbankingnews.com - June 27 at 7:50 PM |
| FY2018 Earnings Estimate for Supernus Pharmaceuticals, Inc. (SUPN) Issued By Cantor Fitzgerald
www.americanbankingnews.com - June 26 at 7:51 AM |
| BidaskClub Upgrades Supernus Pharmaceuticals, Inc. (SUPN) to "Strong-Buy"
www.americanbankingnews.com - June 24 at 3:38 PM |
| Supernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $68.62 Million
www.americanbankingnews.com - June 23 at 1:00 PM |
 | Supernus Pharma (SUPN) Announces Partner, Shire PLC (SHPG), Granted FDA Approval for Mydayis for ADHD
www.streetinsider.com - June 22 at 1:53 PM |
| Supernus Announces that its Partner Shire Receives FDA Approval for Mydayis™ for ADHD
finance.yahoo.com - June 22 at 1:53 PM |
| Brokerages Expect Supernus Pharmaceuticals, Inc. (SUPN) to Announce $0.25 EPS
www.americanbankingnews.com - June 22 at 12:16 AM |
| ETFs with exposure to Supernus Pharmaceuticals, Inc. : June 19, 2017
finance.yahoo.com - June 20 at 8:16 AM |
| Supernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 17 at 6:28 AM |
 | Supernus Pharmaceuticals (SUPN) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 9 at 1:29 AM |
| Revisiting The Investment Case On Supernus - Seeking Alpha
seekingalpha.com - June 8 at 1:08 AM |
| Supernus Pharmaceuticals Inc (SUPN) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 6 at 2:38 PM |
| Supernus Pharmaceuticals Inc (SUPN) VP Sells $398,600.00 in Stock
www.americanbankingnews.com - June 5 at 7:42 PM |
| Supernus Pharmaceuticals Inc to Post Q2 2017 Earnings of $0.25 Per Share, Jefferies Group Forecasts (SUPN)
www.americanbankingnews.com - June 2 at 7:06 AM |
| Piper Jaffray Upgrades Supernus Pharmaceutical On Possible Label Expansion For Seizure Drug - Benzinga
www.benzinga.com - June 2 at 1:09 AM |
| This Top-Rated Biotech Just Popped To A Record High On An Upgrade
finance.yahoo.com - June 2 at 1:09 AM |
| Supernus to Present at Jefferies Healthcare Conference
finance.yahoo.com - June 2 at 1:09 AM |
| Supernus Pharmaceuticals Inc (SUPN) Upgraded to Overweight at Piper Jaffray Companies
www.americanbankingnews.com - June 1 at 11:46 AM |
| Supernus Pharmaceuticals Inc (SUPN) to Post Q3 2017 Earnings of $0.22 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - June 1 at 8:18 AM |
| Supernus Pharmaceuticals' (SUPN) Buy Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - May 31 at 12:34 PM |
| The Psychiatry Pipeline Of Supernus Looks Promising
seekingalpha.com - May 31 at 12:14 PM |
| Supernus Pharmaceuticals Inc (SUPN) VP Sells $89,750.00 in Stock
www.americanbankingnews.com - May 30 at 10:21 PM |
| Supernus Pharmaceuticals Inc (SUPN) Expected to Post Quarterly Sales of $66.93 Million
www.americanbankingnews.com - May 28 at 8:02 AM |
| Supernus Pharmaceuticals Inc (SUPN) VP Sells $191,950.00 in Stock
www.americanbankingnews.com - May 25 at 10:21 PM |
| Edited Transcript of SUPN earnings conference call or presentation 10-May-17 1:00pm GMT
finance.yahoo.com - May 16 at 8:54 AM |
| SunTrust Banks Weighs in on Supernus Pharmaceuticals Inc's Q2 2017 Earnings (SUPN)
www.americanbankingnews.com - May 15 at 7:26 AM |
| Supernus Pharmaceuticals Inc (SUPN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 12 at 2:38 PM |
| Equities Analysts Issue Forecasts for Supernus Pharmaceuticals Inc's FY2017 Earnings (SUPN)
www.americanbankingnews.com - May 12 at 12:32 PM |
| Supernus Pharmaceuticals Inc (SUPN) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - May 11 at 9:02 PM |
| Cowen and Company Reiterates Outperform Rating for Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - May 11 at 4:46 PM |
| Jefferies Group LLC Reiterates $35.00 Price Target for Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - May 11 at 2:56 PM |
| Supernus Pharmaceuticals Inc (SUPN) Expected to Earn FY2017 Earnings of $0.87 Per Share
www.americanbankingnews.com - May 11 at 10:52 AM |
| Supernus Pharmaceuticals Inc (SUPN) Issues Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 10 at 6:20 PM |
Supernus Pharmaceuticals (SUPN) Chart for Saturday, July, 22, 2017
